98%
921
2 minutes
20
Along with other immune checkpoints, cell mmunoglobulin and ucin domain-containing protein (Tim-3) is expressed on exhausted CD4 and CD8 T cells and is upregulated on the surface of these cells upon infection by uman mmunodeficiency irus type (HIV-1). Recent reports have suggested an antiviral role for Tim-3. However, the molecular determinants of HIV-1 which modulate cell surface Tim-3 levels have yet to be determined. Here, we demonstrate that HIV-1 Vpu downregulates Tim-3 from the surface of infected primary CD4 T cells, thus attenuating HIV-1-induced upregulation of Tim-3. We also provide evidence that the transmembrane domain of Vpu is required for Tim-3 downregulation. Using immunofluorescence microscopy, we determined that Vpu is in close proximity to Tim-3 and alters its subcellular localization by directing it to Rab 5-positive (Rab 5) vesicles and targeting it for sequestration within the - olgi etwork (TGN). Intriguingly, Tim-3 knockdown and Tim-3 blockade increased HIV-1 replication in primary CD4 T cells, thereby suggesting that Tim-3 expression might represent a natural immune mechanism limiting viral spread. HIV infection modulates the surface expression of Tim-3, but the molecular determinants remain poorly understood. Here, we show that HIV-1 Vpu downregulates Tim-3 from the surface of infected primary CD4 T cells through its transmembrane domain and alters its subcellular localization. Tim-3 blockade increases HIV-1 replication, suggesting a potential negative role of this protein in viral spread that is counteracted by Vpu.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081912 | PMC |
http://dx.doi.org/10.1128/JVI.01999-19 | DOI Listing |
Pediatr Infect Dis J
September 2025
From the Pediatric Infectious Diseases Unit, Gregorio Marañón University Hospital, Madrid, Spain.
Background: Vaccination is a key strategy to reduce infectious disease mortality. In pediatric heart transplant recipients (HTRs), the use of immunosuppressive therapy weakens immune responses, increasing the risk of viral infections. This study aimed to evaluate the immunogenicity of hepatitis B virus (HBV) revaccination in this vulnerable population.
View Article and Find Full Text PDFAm J Med Genet B Neuropsychiatr Genet
September 2025
The Central Lab, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China.
Autism spectrum disorder (ASD) is a neurodevelopmental condition that is increasingly linked to immune dysfunction and neuroinflammation. Regulatory T cells (Tregs), which are crucial in maintaining immune homeostasis, have been implicated in the pathogenesis of ASD. However, their role in neuroimmune interactions and behavioral outcomes remains poorly understood.
View Article and Find Full Text PDFImmunooncol Technol
September 2025
Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Background: Breast cancer is a systemic disease, yet the impact of tumor molecular subtype and disease stage on the systemic immune landscape remains poorly understood. In this study, we comprehensively analyzed the systemic immune landscape in a large cohort of breast cancer patients, encompassing all molecular subtypes and disease stages, alongside a control group of healthy donors.
Materials And Methods: Using multi-parameter flow cytometry, we assessed the abundance, phenotype, and activation status of diverse innate and adaptive immune cell populations across peripheral blood samples from 355 breast cancer patients and 65 healthy donors.
Front Pharmacol
August 2025
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Background: Recombinant human thrombopoietin (rhTPO) regulates platelet production by promoting megakaryocyte proliferation and has shown promising therapeutic effects in hematopoietic recovery for severe aplastic anemia (SAA). However, its potential impact on immune cells remains unclear.
Methods: This study included 23 patients with SAA, who were divided into two groups based on whether they received rhTPO.
Cureus
August 2025
Department of Urology, The Institute of Medical Science, The University of Tokyo, Tokyo, JPN.
In patients with advanced urothelial carcinoma who have progressed after platinum-based chemotherapy, enfortumab vedotin (EV) improves overall survival compared to standard chemotherapy. Additionally, for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma, the combination of pembrolizumab and EV demonstrates superior efficacy over platinum-based chemotherapy. Hence, EV becomes a standard treatment option.
View Article and Find Full Text PDF